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Abstract
Background: Several different gene expression signatures have been proposed to predict response to therapy and
clinical outcome in lung adenocarcinoma. Herein, we investigate if elements of published gene sets can be
reproduced in a small dataset, and how gene expression profiles based on limited sample size relate to clinical
parameters including histopathological grade and EGFR protein expression.
Methods: Affymetrix Human Genome U133A platform was used to obtain gene expression profiles of 28
pathologically and clinically annotated adenocarcinomas of the lung. EGFR status was determined by fluorescent in
situ hybridization and immunohistochemistry.
Results: Using unsupervised clustering algorithms, the predominant gene expression signatures correlated with the
histopathological grade but not with EGFR protein expression as detected by immunohistochemistry. In a
supervised analysis, the signature of high grade tumors but not of EGFR overexpressing cases showed significant
enrichment of gene sets reflecting MAPK activation and other potential signaling cascades downstream of EGFR.
Out of four different previously published gene sets that had been linked to prognosis, three showed enrichment
in the gene expression signature associated with favorable prognosis.
Conclusions: In this dataset, histopathological tumor grades but not EGFR status were associated with dominant
gene expression signatures and gene set enrichment reflecting oncogenic pathway activation, suggesting that
high immunohistochemistry EGFR scores may not necessarily be linked to downstream effects that cause major
changes in gene expression patterns. Published gene sets showed association with patient survival; however, the
small sample size of this study limited the options for a comprehensive validation of previously reported
prognostic gene expression signatures.
Background
Lung cancer is the most common invasive cancer world-
wide. In the year 2005 approximately 172.570 new cases
were diagnosed in the United States [1]. In addition, it
is the leading cause of cancer associated death [2]. Lung
cancer includes a broad variety of histological subtypes
classified either as small cell lung cancer (SCLC) or
non-small cell lung cancer (NSCLC). NSCLC comprises
approx. 80% of all lung cancers and is further divided
into lung adenocarcinoma (LAC) (~28%), squamous cell
carcinoma (SCC) (~44%), and large cell carcinoma (LC)
(~9%). However, many tumors are composed of mixed
histological types. According to the WHO classification
LAC are subdivided into acinar LAC, papillary LAC,
bronchioloalveolar carcinoma (BAC), and solid LAC
with mucin production as well as a mixed type [2]. The
need for diagnostic improvement is underlined by the
finding that independent lung pathologists find only
41% agreement on LAC subclassification [3].
Gene expression profiling techniques have led to new
approaches to cancer classifications [4]. A number of
studies have applied gene expression analyses to identify
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tering analyses have led to the identification of
gene expression profiles associated with patient
d i s e a s ef r e es u r v i v a lo ro v e r a l lo u t c o m ei nN S C L C
[5,12,16,21,22,25,26,29]. In particular, expression profiles
of LAC did not correlate with tumor grade or conven-
tional histopathological subgroups [30,31]. Garber et al.
and Bhattacharjee et al. applied unsupervised hierarchi-
cal clustering to classify human lung adenocarcinomas
[9,14]. Although these studies used different experimen-
tal microarray platforms, i.e. oligonucleotide and cDNA
microarray, it was surprising to find that both studies
show a high congruency in terms of the identified gene
signatures [9,14]. Beer et al. could demonstrate that
gene expression profiles can be used to calculate a risk
index predicting patient survival in early stage LAC [8].
This gene expression signature conferring poor prog-
nosis was independent of stage of disease at time of
diagnosis.
A subset analysis of 18 LAC provided by Kikuchi et al.
identified an expression signature of 40 genes separating
lymph-node positive from lymph-node negative cases
[19]. Balko et al. applied gene expression data derived
from cell lines showing differential sensitivity to EGFR
tyrosine kinase inhibitors to classify human LAC [6].
Other studies also correlated gene expression
profiles with prognosis and risk of recurrence
[12,16,20,21,25,26,29,32]. In these studies subsets of
genes differentially expressed in tumors could predict
survival differences among patients with LAC within
consistent morphological subgroups. Shedden et al. col-
lected gene expression data and clinical data of 442
LAC from six contributing institutions. In their multi-
site blinded validation approach the combination of
training-testing methods and clinical data (stage, age
and sex) showed the best results in predicting the over-
all survival [32].
Potti et al. identified gene expression profiles predicting
the risk of recurrence in a cohort of 198 NSCLC patients,
among them 89 LACs [25]. They computed nine meta-
gene-signatures containing altogether 133 elements using
the metagene construction model and binary prediction
tree analysis. The metagene-signatures were generated
from a training cohort to predict the risk of recurrence
and are available online as supplemental information.
These signatures have been validated in two multicenter
cooperative study group collectives.
A similar study by Larsen et al. provided a 54-gene sig-
nature predicting the risk of recurrent disease indepen-
dently of tumor stage [21]. Both studies point to the
potential of gene expression methodologies to refine the
accuracy of clinical prognosis for patients undergoing
resection for primary LAC especially in early disease
stages.
In our study we investigate if elements of published
gene sets can be reproduced in a small independent
dataset, and how gene expression profiles based on lim-
ited sample size relate to clinical parameters including
histopathological grade and EGFR protein expression.
Methods
Patients and samples
Tissues were selected from the tumor bank of the Insti-
tute of Pathology, University Hospital Freiburg. All tis-
sue samples were collected for diagnostic purposes and
studied in accordance with national ethical principles.
The investigation protocol was approved by the institu-
tional review board (No.14/2004). Clinico-pathological
data were collected in collaboration with the Depart-
ment of Thoracic Surgery, University Hospital Freiburg.
Representative 3 μm sections of the tumor tissues were
H&E stained and reviewed for tissue quality, cellular
composition, confirmation of the histopathological diag-
nosis and tumor-grading independently by three surgical
pathologists (GK, MW, AzH) according to the World
Health Organization criteria and current TNM-classifi-
cation [2]. Discordant cases have been discussed in com-
mon and a consensus was defined for the subsequent
statistical analyses. Only samples with a tumor-cell con-
tent of more than 90% were used for molecular analyses.
We analyzed tumor samples of 28 patients who under-
went surgery between 2002 and 2004 at the Department
of Thoracic Surgery, University Hospital Freiburg. The
mean age of the patients was 65.3 years. Forty-eight per-
cent of the patients were male and 52% female. All 28
tumors were initially classified as mixed type adeno-
carcinomas of the lung. For molecular analyses areas
with homogeneous acinar growth pattern were selected.
The majority of the tumors was moderately (n = 15) or
poorly differentiated (n = 10). The patients were oper-
ated with a curative intent. Therefore the operation was
performed in early clinical stages (24% at T1-stage and
65.5% at T2-stage). In 83% lymph-node metastases were
present at the time of surgery. Only in one case distant
metastases could be evaluated. Two cases revealed resi-
dual tumor after surgical treatment. Clinico-pathological
data are summarized in table 1.
Gene expression profiling
Total RNA was extracted from each frozen tumor speci-
men using the Qiashredder (Qiagen, Hilden, Germany)
and the RNeasy Kit (Qiagen, Hilden, Germany) and bio-
tinylated cRNAs were generated according to the manu-
facturer’s protocol (Affymetrix, Santa Clara, CA). In
brief, the biotinylated cRNA was purified using RNeasy
affinity columns (Qiagen, Hilden, Germany). RNA qual-
ity control was assessed by the 260 nm and 280 nm
absorbance ratio and gel electrophoresis. Further sample
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scanning was performed using the standard Affymetrix
protocol. Five μg of total RNA from each tumor speci-
men, T7-oligo(dT) primers, and Superscript II RT (Invi-
trogen GmbH, Karlsruhe, Germany) were used for first
strand cDNA synthesis. After second strand synthesis, in
vitro transcription was performed using Enzo Transcript
Labeling Kit (Enzo Life Science, Farmingdale, NY) to
generate biotinylated cRNA targets. cRNA targets were
fragmented at 94°C for 35 minutes and 15 μgo fi tw a s
hybridized to HG-U133A chips (Affymetrix Inc, Santa
Clara, CA, USA) at 45°C for 16 hours. The arrays were
washed and stained with 10 μg/ml streptavidin-phycoer-
ythrin. After signal amplification with biotinylated anti-
streptavidin antibodies the arrays were scanned using
the GeneChip® Scanner 3000. The HG-U133A chip
contains 22.283 probe sets representing 14.564 human
genes.
Data analysis
Following standard data acquisition, the scanned images
were quantified according to the Affymetrix GeneChip
Manual (Affymetrix Inc., Santa Clara, CA) by using the
Data Mining Tool (DMT) 2.0, and Microarray Database
software (accessed June 2004) using the Entrez Gene
definitions. The probe set IDs were annotated and, for
comparison with published gene expression signatures,
manually cross-referenced using NetAffx Analysis Cen-
ter provided by the homepage of the manufacturer
(http://www.affymetrix.com, accessed May 2008) [33].
The signals were globally normalized and scaled to a
s i g n a li n t e n s i t yo f5 0 0 .A l lo ft h em i c r o a r r a y sw e r e
examined for surface defects, grid placement, back-
ground intensity, housekeeping gene expression
(GAPDH and b-Actin), and 3’-/5’- ratio of probe sets.
For hybridization control the signals of the controls
(BioB, BioC, BioD, and Cre), the scale factors and the
background intensities of each array were calculated and
compared. The present calls of hybridized microarrays
showed a range from 33.2% to 59.9% of all investigated
elements (median 55.05%). The mean 3’-/5’-r a t i oo f
probe sets for GAPDH and b-Actin was 1.07 (standard
deviation: 0.6) and 1.44 (standard deviation: 1.9), respec-
tively. The spike-in controls showed an adequate expres-
sion in all cases. The average background signal -
generally recommended being less than 100 - varied
between 40.88 and 95.38 (median 53.73). The microar-
ray dataset described in this work, including .cel-files,
was deposited at the Gene Expression Omnibus under
the series accession GSE17475 [34].
Quality controls were performed using Microarray
Suite 5.0 software provided by Affymetrix http://www.
affymetrix.com according to the manufacturer’sr e c o m -
mendations. Data acquisition for gene expression analy-
sis, starting from the .cel files, was performed using the
robust multiarray average (RMA) algorithm published
by Irizarry et al [35,36] Prior to analysis by supervised
and unsupervised clustering algorithms, the RMA-pro-
cessed dataset was filtered applying a standard variation
filter (default) provided by the dChip-Software V1.3
http://www.dchip.org, version 2003. Two-dimensional
hierarchical clustering was performed in D-Chip (V1.3,
2003). Statistical analyses were performed using the
publicly available R-Software V2.5.0 http://www.r-pro-
ject.org[37]. Gene Set Enrichment Analysis (GSEA) was
performed using publicly accessible software provided
by the Broad Institute http://www.broadinstitute.org/
gsea/msigdb/downloads.jsp[38,39]. To identify biologi-
cally relevant gene sets for GSEA analysis, the search
function provided by the website was used to identify
Table 1 Clinico-pathological data of 28 LAC patients used
for the generation of expression profiles.
Code Age Sex Grade T N M R Smoker
LAC_19 58 M 2 2 2 0 0 yes
LAC_20 59 F 3 2 1 0 1 yes
LAC_21 75 M 2 2 0 0 0 yes
LAC_22 60 F 2 1 2 0 0 yes
LAC_23 47 F 3 2 1 0 1 n.a.
LAC_24 61 M 2 4 2 0 0 yes
LAC_25 64 F 3 2 2 1 0 yes
LAC_26 70 M 2 1 0 0 0 yes
LAC_36 72 F 3 2 2 0 0 yes
LAC_37 67 F 2 2 0 0 0 yes
LAC_38 82 M 2 4 2 0 0 yes
LAC_39 69 M 1 2 2 0 0 yes
LAC_40 83 F 1 1 0 0 0 yes
LAC_41 51 F 2 2 0 0 0 yes
LAC_42 78 F 3 2 0 0 0 no
LAC_43 59 F 2 4 2 0 0 yes
LAC_45 69 M 2 2 0 0 0 yes
LAC_47 56 M 2 1 2 0 0 yes
LAC_49 72 M 3 2 2 0 0 yes
LAC_51 65 M 3 2 2 0 0 yes
LAC_52 70 F 2 2 1 0 0 yes
LAC_53 62 F 3 2 1 0 0 yes
LAC_54 54 F 2 1 0 0 0 yes
LAC_55 77 F 2 2 0 0 0 yes
LAC_56 67 M 3 2 0 0 0 yes
LAC_57 73 M 2 1 0 0 0 yes
LAC_58 56 M 3 2 1 X 0 n.a.
LAC_61 76 F 1 2 0 X 0 n.a.
Classification according to WHO and TNM-Classification (6
thedition 2002).
LAC = lung adenocarcinoma; Age = age at operation; F = female; M = male;
T = tumor stage; N = absence (0), presence of ipsilateral peribronchial and/or
ipsilateral hilar lymph node metastasis (1) or ipsilateral mediastinal and/or
subcarinal lymph node metastasis (2); M = absence (0) or presence (1) of
distant metastasis; R = absence (0) or presence (1) of residual tumor;
X = classification could not be assessed; n.a. = data not available.
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downstream signalling, us i n gE G F R ,E R K ,M A P Ka s
search terms http://www.broadinstitute.org/gsea/msigdb/
collections.jsp#C2. The algorithm computes an enrich-
ment score (ES) that is based on Kolmogorov-Smirnov
statistics, provides a nominal p-value, and corrects for
multiple testing by calculating the false discovery rate
(FDR). A significance level of FDR < 0.05 was accepted.
For a detailed mathematical description of the statistical
methods, see Ref. [39].
Tissue microarray
In order to perform standardized immunohistochemical
analyses we generated a tissue microarray (TMA) of the
28 primary LAC containing 3 representative cores of
each case to account for potential tumor heterogeneity.
In cases with variable staining intensities across cores,
the mean was recorded.
Fluorescence in-situ hybridization
Paraffin sections of 5 μm were dewaxed and washed
shortly with PBS. As pretreatment the tissue sections
were heated in citrate-buffer for 17 minutes and incu-
bated with Pronase E at 37°C for 3 minutes. Denatura-
tion was performed by formamide 70% for 15 minutes
at 75°C and afterwards stabilized by ethanol. The sec-
t i o n sw e r et h e nh y b r i d i z e dw i t ht h eV y s i sE G F R / C E P 7
D u a lC o l o rP r o b ef o r2 0h o u r sa t3 7 ° C ,a f t e rw a s h i n g
the probes were counterstained with Dapi.
EGFR immunohistochemistry
All slides of the TMA were submitted to immunohisto-
chemistry (IHC) at the same time. In brief, 3 μmt h i c k
paraffin sections were analyzed for protein expression of
non-phosphorylated EGFR by IHC using the Dako
EGFR pharm Dx™ kit (Dako, Germany). The staining
procedure was performed according to the provided
automated staining protocol on a DAKO autostainer.
Afterwards the slides were immersed in hematoxylin for
3 minutes for nuclear counterstaining. For scoring of
EGFR expression, the following qualitative scale: 0 -
“negative”,1-“weak staining”,2-“moderate staining”,
3-“strong staining” was applied. Further the percentage
of positive tumor cells was calculated. Both scoring sys-
tems were applied for membranous and cytoplasmic
positivity.
Results
Unsupervised Analysis of Microarray Data
After normalization two-dimensional hierarchical clus-
tering analysis was applied to determine if any clinical
or biological subset existed in our set of 28 LAC. A final
filtered gene list of 2777 probes selected by variation fil-
ter provided by dChip-software was used. LACs were
clustered into two distinct groups of 16 and 12 samples
(fig. 1). The two clusters revealed significant differences
with respect to histopathological grading (grade 3 vs.
grade 1 and 2; p < 0.001). All well differentiated LAC
(G 1; n = 3) were found in cluster 1. In contrast, all
poorly differentiated LAC (G 3; n = 10) were present in
cluster 2. Although the majority (n = 9) of moderately
differentiated LAC (G2) was found in cluster 1, some of
these tumors were grouped into cluster 2 (n = 6). No
significant association between the two clusters and
tumor stage, smoking status, gender, age or immunohis-
tochemical EGFR protein expression was identified.
Further, the major clusters obtained by unsupervised
analysis did not reflect the clinical outcome with regard
to overall survival.
EGFR immunohistochemistry and FISH analysis in Relation
to EGFR mRNA
Due to multiple usage of the TMA in two cases the par-
affin-embedded material was exhausted. Of the remain-
ing 26 LAC samples nine showed no membranous
expression of EGFR. In tumors with positive EGFR-
immunohistochemistry 65.38% (+/- 36.35%) of the cells
showed membranous and 88.64% (+/- 32.74%) cytoplas-
matic staining. Complete membranous staining was seen
in 6 cases (23.08%). For these, the intensity score was 3.
The incomplete membranous stain was moderate (inten-
sity score 2) in three cases, and strong (intensity score 3)
in the remaining eight tumors. The gene expression
values obtained by microarray analyses were concordant
with EGFR detection on the protein level measured by
IHC with p < 0.01 for probe set 201983_s_at, and p <
0.02 for probe set 201984_s_at (Spearmans Rank Order
Correlation, see fig. 2 and 3).
EGFR-gene amplification was investigated with FISH
analysis. On average 3.89 (+/- 1.12) signals for the 7p12
EGFR locus and 3.12 (+/- 0.82) CEP 7 signals were
detected within the tumor cells. The 7p12/CEP 7 ratio
was 1.25 on average. No case revealed EGFR-gene locus
(7p12/CEP 7 ratio > 2) amplification. No correlation
was seen between number of EGFR-FISH signals and
the intensity of immunohistochemical staining results.
Results of the immunohistochemistry and the FISH ana-
lysis are shown in fig. 2 and summarized in table 2.
Pathway Analysis
In a supervised analysis approach, all genes (unfiltered
gene set) were ranked according to differential expres-
sion in (1) EGFR score 3 vs. EGFR score 0&1&2, (2)
EGFR score 2&3 vs. EGFR score 0&1, and (3) histo-
pathological grade 3 vs. grade 2&1. Gene Set Enrich-
ment Analysis (GSEA) was used to test for enrichment
of the pathway-related gene sets in the over expressed
(top-ranked) or the down regulated (bottom-ranked)
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Page 4 of 12Figure 1 Hierarchical cluster analysis identifies tumor grade as dominant substructure. Hierarchical clustering of 2777 features selected by
variation filter shows that the dominant substructure of the dataset is driven by tumor grade and not by EGFR status. All grade 3 tumors were
segregated in one major branch. No correlation of EGFR status and the results of hierarchical clustering could be obtained. The upper bar shows
the histopathological tumor grade (turquoise = grade 1, blue = grade 2 and red = grade 3). The second bar shows the EGFR expression on
protein level (pink = no protein expression, green = incomplete membranous stain and yellow = complete membranous stain). The expression
values are indicated by color code (blue = no gene expression and red = high gene expression).
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Page 5 of 12Figure 2 Quantitative and qualitative assessment of EGFR status. A-D: Immunohistochemical stain for EGFR of primary lung
adenocarcinoma (magnification: 200×). A) No membranous or cytoplasmic stain. B) Weak mostly incomplete membranous stain combined with
moderate cytoplasmic stain. C) Moderate mostly incomplete membranous stain combined with weak cytoplasmic stain. D) Strong mostly
complete membranous stain combined with strong cytoplasmic stain. E and F: E) Fluorescence in-situ hybridization for EGFR (locus 7p12, red)
and CEP7 (locus 7p11.1-q11.1, green) of primary lung adenocarcinoma showing no amplification of the EGFR-gen. F) Corresponding
immunohistochemical stain for EGFR showing strong mostly incomplete membranous staining combined with moderate cytoplasmic staining.
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Page 6 of 12genes in each of the supervised analyses. When the
dataset was ranked according to differential expression
in histopathological grade 3 cases vs. cases classified as
grade 2&1, the following gene sets showed significant
enrichment after correction for multiple testing: ERBB
signaling (KEGG), NSCLC related signaling (KEGG),
EGFR/SMRT (Biocarta), and FAS anti-apoptotic signal-
ing (Biocarta). Summarized results are shown in fig. 4A-
D. In contrast, no significant enrichment was observed
when the dataset was ranked according to EGFR status.
For completeness, the other clinical parameters (age,
nodal stage etc.) were used to group cases for additional
GSEA runs; after correcting for multiple testing none of
these analyses showed any statistically significant enrich-
ment of the selected gene sets.
Assessment of published prognostic gene expression
signatures
The published gene signatures were used in two analysis
approaches: In an unsupervised analysis, two-dimen-
sional clustering was performed in the space of all genes
that were represented on both the published and the
U133A platform. Clustering in the space of the “Potti
signature”, defined as the communality of all genes
described as having any prognostic significance (overlap
between platforms: 114 probesets, representing 105
Genes, Additional file 1: Supplemental table S1),
resulted in co-segregation of cases with similar outcome
in two major clusters, one of which included 83% of
long-term surviving patients, whereas the other cluster
comprised 50% of patients with favorable outcome.
Clustering in the space of the other signatures (Larsen
2007, Balko 2006, Chen 2008) did not produce compar-
able segregation of long term survivors vs. patients with
unfavorable outcome [6,12,21]. In a second approach,
GSEA was employed to test for enrichment of the signa-
ture components at the top of the total data set, ranked
according to differential expression of genes between
long-term and short-term survival. The gene sets of the
Balko, and Chen but not of the Larsen signature showed
statistically significant enrichment at the top of data set
ranked by survival. The Potti signature showed a trend
for enrichment but did not meet statistical significance
(see fig. 4). In summary, these results suggest that the
association between publish e dp r o g n o s t i cg e n ee x p r e s -
sion signatures and outcome is detectable, but does not
appear to be a dominant feature of this small indepen-
dent data set.
Discussion
In the present study we analyzed 28 LAC for gene
expression profile by using the Affymetrix chip platform.
Unsupervised hierarchical cluster analysis led to the
identification of two subclasses of LAC. We found two
Figure 3 EGFR expression congruency. A: Comparison of the intensity of positive staining of EGFR obtained by immunohistochemistry and
gene expression measured by Affymetrix gene chips: Gene expression values are congruent with EGFR detection on the protein level. The
upper bar shows the EGFR expression on protein level (pink = no protein expression, green = incomplete membranous stain and yellow =
complete membranous stain). The expression values of elements representing EGFR gene expression (middle) are indicated by color code shown
in the lowest bar (blue = low gene expression and red = high gene expression). In B the results of the Spearmans Rank Order Correlation of the
gene expression values obtained by microarray analyses and EGFR protein levels measured by IHC are shown.
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histopathological grading. All well differentiated LAC (G
1) were found in cluster 1. In contrast, all poorly differ-
entiated LAC (G 3) were present in cluster 2. The inter-
esting finding that some of the moderately differentiated
LAC were found in cluster 2, indicates that this subset
of moderately differentiated LAC already share gene
expression profiles with poorly differentiated LAC,
which yet is not reflected by histopathology. Thus, gene
expression analysis might help to identify a subgroup of
G2-LAC, which already reveals the molecular features of
poorly differentiated LAC but lacks typical histomorpho-
logical dedifferentiation. These features could be asso-
ciated with a more aggressive biological behavior of the
tumor cells.
The grading system provided by the WHO classifica-
tion is poorly defined and based on conventional histolo-
gical criteria, including the extent to which the
architectural pattern of the tumor resembles normal lung
tissue and cytological atypia. In our study three experi-
enced surgical pathologists reevaluated all cases for con-
firmation of the diagnosis and tumor grade. Discordant
cases were discussed and a consensus grading was
worked out. A recent study by Petersen et al. proposes a
grading system for LAC based on the nuclear size varia-
bility. They could demonstrate that the core size variabil-
ity of LAC tumor cells correlated significantly with the
patient’s survival [40]. Our data indicate that the conven-
tional grading system provided by the WHO classification
is still unsatisfactory and does not reflect the biology of
the tumor. Further studies correlating different grading
systems and gene expression data will be necessary to
answer this question profoundly.
In our study EGFR protein expression and number of
EGFR gene copies were analyzed by immunohistochem-
istry and FISH, respectively. Consistent with the litera-
ture 86% (24/28 cases) of investigated tumor samples
showed an expression of EGFR on protein level [41-43].
No correlation of EGFR status and the results of gene
expression profiling could be detected. A similar result
was found by Balko et al. who applied a gene signature
predicting the sensitivity to EGFR tyrosine kinase inhibi-
tors obtained from various cell lines to classify human
lung adenocarcinomas [6].
Table 2 Results of the EGFR immunohistochemistry and FISH analysis of 26 LAC patients.
EGFR Immunohistochemistry EGFR FISH
Membrane Cytoplasm
Code Membrane Intensity Percent Intensity Percent Centromere EGFR Locus Ratio
Lu_19 complete 3 90 2 90 4.90 6.13 1.25
Lu_20 negative 0 0 0 0 3.94 4.47 1.13
Lu_21 incomplete 2 40 1 60 3.30 3.38 1.02
Lu_22 incomplete 3 90 2 90 2.96 3.31 1.12
Lu_24 complete 2 80 1 90 3.10 3.96 1.28
Lu_25 incomplete 3 20 2 70 3.05 3.44 1.13
Lu_26 complete 3 90 3 90 3.00 4.07 1.36
Lu_36 incomplete 3 70 1 90 3.23 3.99 1.24
Lu_37 incomplete 3 90 2 90 3.14 4.44 1.41
Lu_38 complete 3 70 3 90 4.95 6.13 1.24
Lu_39 negative 0 0 3 40 2.61 3.22 1.24
Lu_40 negative 0 0 1 10 2.35 2.59 1.10
Lu_41 negative 0 0 2 50 3.15 3.84 1.22
Lu_42 incomplete 3 40 3 80 3.55 4.06 1.14
Lu_43 incomplete 2 70 1 80 3.92 6.26 1.60
Lu_45 incomplete 3 60 2 30 2.90 4.12 1.42
Lu_47 complete 3 90 1 90 2.00 2.12 1.06
Lu_49 negative 0 0 0 0 2.87 3.91 1.36
Lu_51 incomplete 2 20 2 40 2.86 3.66 1.28
Lu_52 negative 0 0 1 10 1.93 2.22 1.15
Lu_53 complete 3 80 2 90 2.00 3.31 1.66
Lu_54 incomplete 3 70 2 40 3.96 5.00 1.26
Lu_55 negative 0 0 1 20 2.59 2.45 0.95
Lu_56 negative 0 0 0 0 2.25 4.12 1.83
Lu_57 incomplete 3 80 2 90 2.52 2.54 1.01
Lu_61 negative 0 0 3 80 2.29 2.49 1.09
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Page 8 of 12Figure 4 GSEA Analysis. A-D summarize the results of the pathway-analysis: Four of the gene sets relevant for EGFR-related signaling made
available by the GSEA web site (gene set collection “C2”) showed statistically significant enrichment towards the top of the data set when it was
ranked according to differential gene expression between grade 3 vs. grade 1&2 tumors. E-H show the results of GSEA, testing for enrichment of
published prognostic gene expression signatures in our small independent data set when it was ranked according to differential gene
expression between long-term survivors and patients with unfavorable outcome: The signatures of Balko et al. and Chen et al. were significantly
enriched, and the Potti et al. signature showed a clear trend towards enrichment although it did not meet statistical significance. The Larsen
signature was not overrepresented at the top of the ranked data set in this analysis. ES = enrichment score, FDR = false discovery rate. A
significance level of FDR < 0.05 was accepted.
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amplification frequency of approximately 10%, no ampli-
fication of the EGFR locus was observed in this study
[41,43]. This discrepancy might in part be explained by
the relative small number of LAC analyzed in this study.
On the other hand our study, in contrast to other pub-
lished data mainly arising from the US, originates from
a homogeneous south German population, possibly
reflecting genetic differences between different popula-
tions. No correlation between microarray data and
TNM tumor stage, smoking status or gender was found
[32,44].
In a supervised approach we performed a pathway
analysis confirming an overexpression of genes involved
in signal cascades downstream to EGFR. The pathway
related genes showed a correlation with the histopatho-
logical tumor grade (grade 3) but not with the EGFR
protein expression as determined by the standardized
Dako EGFR pharm Dx™ kit for detection of non-phos-
phorylated EGFR, reflecting membrane protein expres-
sion but not the activation-status of EGFR. This
suggests that the immunohistochemical analysis may be
less sensitive than gene expression profiles to detect bio-
logically relevant tumor characteristics linked to EGFR
signaling.
Several studies have used expression profiling to char-
acterize prognosis in lung cancer
[5,6,12,16,21,22,25,26,29]. We choose the works by
Balko et al., Larsen et al., Potti et al. and Cheng et al.
for further analysis.
Individual unsupervised cluster analysis in the space of
each of the genesets (combining all genes reported as
being relevant per signature) failed to define robust clus-
ters of cases, except the signature of 114 probe sets pub-
lished by Potti et al. that resulted in some co-segregation
of cases with similar outcome in our dataset [25].
GSEA analysis, used to test for enrichment of the indi-
vidual prognostic gene sets confirmed significant over-
representation of the signatures of Balko and Chen, and
a trend towards enrichment of the Potti signature, in
t h et o pg e n e sr a n k e db yd i f f e r e n t i a le x p r e s s i o nb e t w e e n
long term survivors and patients with unfavorable clini-
cal outcome, indicating an association between these
gene expression signatures and the survival of the
patients that remains to be characterized in larger sam-
ple sets [6,12,25].
Conclusions
This study confirmed the limited value of published
gene expression analyses to identify patients with poor
outcome in a LAC dataset, as recently shown in a large
multicenter study, particularly when applying it to smal-
ler independent data sets [32]. In the light of the present
data it seems unlikely, that a signature of only few
mRNA measurements will be sufficient to reliably pre-
dict response/prognosis, particularly if applied to single
cases or smaller series of patient samples. The gene
expression signatures observed in this study seem to be
mainly driven by the tumor grade, even more so than
by EGFR protein expression detected by IHC and other
clinical parameters. Therefore, a careful histopathologi-
cal assessment and the use of consensus pathologist
panels are recommended for future studies to standar-
dize histopathological annotation and to combine gene
expression signatures with robust clinical parameters.
Additional file 1: Supplemental table S1. Genes extracted from nine
metagene signatures according to Potti et al. The table contains detailed
information of the Affymetrix probe set numbers, gene names and gene
symbols of the 114 genes extracted from nine metagene signatures
according to Potti et al.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
77-S1.XLS]
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